Oncorus, Inc., a clinical stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: oncorus.com
DEFA14A - Oncorus, Inc. (0001671818) (Filer)
15-12G - Oncorus, Inc. (0001671818) (Filer)
DEFA14A - Oncorus, Inc. (0001671818) (Filer)
8-K - Oncorus, Inc. (0001671818) (Filer)
S-8 POS - Oncorus, Inc. (0001671818) (Filer)
S-8 POS - Oncorus, Inc. (0001671818) (Filer)
S-8 POS - Oncorus, Inc. (0001671818) (Filer)
S-8 POS - Oncorus, Inc. (0001671818) (Filer)
RW - Oncorus, Inc. (0001671818) (Filer)
8-K - Oncorus, Inc. (0001671818) (Filer)